RWell by RespondWellCheck Eligibility
    Tirzepatide treatment

    Tirzepatide

    Dual GIP/GLP-1 for powerful weight loss

    First order: $160

    Second and subsequent refills $279/per 30-day supply of medication or $499 for a 90-day supply of medication. Automatic refills – pause, delay or cancel anytime – just make those changes at least 48 hours before your next refill date.

    Prescription Required
    Doctor Prescribed
    100% Online
    UPS 2nd Day Air
    No Waiting Rooms
    No Membership Fees
    FSA/HSA Eligible
    Check Eligibility →Free provider visit • You pay $0 if not approved

    How RWell Works

    1

    Choose

    Pick your treatment and complete a quick health intake.

    ⏱ 2 MINUTES
    2

    Consult

    A licensed provider reviews your info and medical history.

    ⏱ 5 MINUTES
    3

    Prescribe

    If appropriate, your prescription is sent to our pharmacy.

    ⏱ <4 HOURS
    4

    Deliver

    Your medication ships discreetly to your door.

    ⏱ <1 WEEK*

    *Timelines shown reflect our average turnaround times and are not guaranteed.

    Ready to Get Started?

    Check Eligibility for Tirzepatide

    *Clinical outcomes based on published tirzepatide trials, including SURMOUNT-1 (weight loss)¹, SURPASS-2 (glucose & metabolic health)², SURPASS-4 (cardiovascular outcomes)³, and SURMOUNT-OSA (sleep apnea)⁴. Compounded versions of Tirzepatide are not associated with Eli Lilly & Company and/or its genuine MOUNJARO® and/or ZEPBOUND® products. Compounded versions of Tirzepatide are not FDA approved, and neither the FDA nor any global regulatory agency has reviewed these products for safety, quality, or efficacy. GLP-1s may cause serious side effects, including possible thyroid tumors, including cancer. See the 'Safety Information' links below for more details.

    1 Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.

    2 Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515.

    3 Del Prato, S., Kahn, S. E., Pavo, I., et al. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). The Lancet, 398(10313), 1811–1824.

    4 Malhotra, A., Grunstein, R. R., Gao, L., et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine, 391(13), 1193–1205.